QIAGEN shareholders back CEO Pratt for a seat on the Managing Board
QIAGEN shareholders approved CEO Jonathan M. Pratt as Managing Director and board member at an extraordinary meeting, per TradingView. He took office September 1, 2026.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
According to a report published by TradingView, QIAGEN N.V. shareholders gave an overwhelming vote of support to Jonathan M. Pratt, confirming him as a Managing Director with a place on the company's board. The decision was taken at an Extraordinary General Meeting. Pratt became QIAGEN's chief executive on September 1, 2026, and now sits on the board alongside CFO Roland Sackers.
The same meeting also approved a discharge for Thierry Bernard covering his board service through September 1, 2026, when he left the chief executive post and the Managing Board. The report did not specify any financial impact from these decisions.
why it matters
Formally, this confirms a leadership change that already took place in September, so the vote alone is unlikely to move QIAGEN's shares. For investors in the life sciences sector, operating results and guidance matter far more than outcomes of shareholder meetings. The story signals continuity, with the chief executive and finance chief now working together on the board.
tags
instruments
sources
- QIAGEN N.V. (QIA) Shareholders Approve CEO Jonathan Pratt to Managing Board — TradingView, 6 November 2026 at 15:00 UTC
- QIAGEN Shareholders Overwhelmingly Approve Jonathan M. Pratt as Managing Director — TradingView, 6 November 2026 at 15:00 UTC
- Qiagen Shareholders Approve Jonathan M. Pratt As Managing Director — Reuters, 6 November 2026 at 15:00 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗